Initial Clinical Data Reported From Immutep's Efti Combined With Radiotherapy And Checkpoint Inhibitor From Phase II Trial In Soft Tissue Sarcoma
Initial Clinical Data Reported From Immutep's Efti Combined With Radiotherapy And Checkpoint Inhibitor From Phase II Trial In Soft Tissue Sarcoma
Immutep的Efti联合放射疗法和软组织肉瘤二期试验的检查点抑制剂报告的初步临床数据
Novel triple combination of efti with radiotherapy and anti-PD-1 therapy is well tolerated and has led to encouraging initial efficacy data in EFTISARC-NEO Phase II trial
Four of six patients treated have very good, near-complete pathologic responses (primary endpoint of study) that are rarely observed with standard therapies
Soft tissue sarcoma is a hard-to-treat orphan disease with poor prognosis & high unmet medical need
Additional data from EFTISARC-NEO planned for a medical conference in H2 CY2024
efti与放射治疗和抗PD-1疗法的新型三重组合具有良好的耐受性，并已在EFTISARC-NEO II期试验中获得了令人鼓舞的初步疗效数据
接受治疗的六名患者中有四名具有非常好、接近完整的病理反应（主要研究终点），而标准疗法很少能观察到这种反应
软组织肉瘤是一种难以治疗的孤儿病，预后不佳，未得到满足的医疗需求很高
来自 EFTISARC-NEO 的更多数据计划在 H2 CY2024 的医学会议上举行
SYDNEY, AUSTRALIA, May 02, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company...
澳大利亚悉尼，2024 年 5 月 2 ...
登录免费看全文
登录/注册